NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc.

佛罗里达州北棕榈滩，2026年8月4日（环球电讯社）——SRX Global Inc.（纽约证券交易所美国市场代码：SRXH）（以下简称“公司”或“SRX”），一个致力于通过对高置信度运营公司和战略资产的投资来创造长期股东价值的人工智能赋能平台，今日宣布已收购Vistagen Therapeutics, Inc.的股份。

(Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines..

Vistagen（纳斯达克股票代码：VTGN）是一家处于临床后期阶段的生物制药公司，通过开创性的鼻至脑神经回路技术，致力于开发和商业化一类名为“pherines”的新型鼻用候选产品。

The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.

该公司认为Vistagen的股价被低估，并欢迎与其领导团队和董事会进行建设性沟通，共同探讨如何释放股东价值的方案。

About SRX Global Inc.

关于SRX全球公司

SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors..

SRX Global 是一个由人工智能驱动的平台，专注于通过对高确信度的运营公司、战略资产以及技术赋能的机会进行投资，创造长期股东价值。公司利用专有技术、数据分析和严谨的资本配置，在多个行业识别并管理投资组合。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'expect,' 'intend,' 'aim,' 'plan,' 'may,' 'could,' 'target,' and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

本新闻稿包含1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。“相信”、“预期”、“打算”、“目标”、“计划”、“可能”、“可以”、“旨在”等词语及类似表述旨在识别前瞻性陈述。这些陈述基于当前的预期和假设，受各种风险和不确定性的影响，可能导致实际结果与明示或暗示的结果存在重大差异。

These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law..

这些风险包括但不限于：完成拟议交易的能力、股东批准、市场状况、监管考量以及公司在向美国证券交易委员会提交的文件中描述的其他风险。前瞻性陈述仅反映其作出之日的情况，除非法律另有要求，公司不承担更新这些陈述的义务。

Company Contact

公司联系方式

SRX Global

SRX 全球

Kent Cunningham, Chief Executive Officer

肯特·坎宁安，首席执行官

Investor Relations Contact

投资者关系联系人

KCSA Strategic Communications

KCSA战略传播

Valter Pinto, Managing Director

瓦尔特·平托，总经理

212-896-1254

212-896-1254

srx@kcsa.com

srx@kcsa.com